DK1350521T3 - Immunoterapeutiske kombinationer til behandling af tumorer - Google Patents

Immunoterapeutiske kombinationer til behandling af tumorer

Info

Publication number
DK1350521T3
DK1350521T3 DK01999388T DK01999388T DK1350521T3 DK 1350521 T3 DK1350521 T3 DK 1350521T3 DK 01999388 T DK01999388 T DK 01999388T DK 01999388 T DK01999388 T DK 01999388T DK 1350521 T3 DK1350521 T3 DK 1350521T3
Authority
DK
Denmark
Prior art keywords
tumors
treatment
immunotherapeutic combinations
immunotherapeutic
combinations
Prior art date
Application number
DK01999388T
Other languages
Danish (da)
English (en)
Inventor
Rodriguez Rolando Perez
Marinello Gisela Maria Gonzalez
Ramos Tania Crombet
Delgado Irene Beausoleil
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of DK1350521T3 publication Critical patent/DK1350521T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001104Epidermal growth factor receptors [EGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001131Epidermal growth factor [EGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001134Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01999388T 2000-12-08 2001-12-06 Immunoterapeutiske kombinationer til behandling af tumorer DK1350521T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
PCT/CU2001/000012 WO2002045747A1 (es) 2000-12-08 2001-12-06 Combinaciones inmunoterapeuticas para el tratamiento de tumores

Publications (1)

Publication Number Publication Date
DK1350521T3 true DK1350521T3 (da) 2008-11-10

Family

ID=40261022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01999388T DK1350521T3 (da) 2000-12-08 2001-12-06 Immunoterapeutiske kombinationer til behandling af tumorer

Country Status (26)

Country Link
US (2) US20020160014A1 (sl)
EP (2) EP2005996A3 (sl)
JP (2) JP2005519023A (sl)
KR (1) KR20030064416A (sl)
CN (1) CN1326566C (sl)
AR (1) AR031641A1 (sl)
AT (1) ATE403438T1 (sl)
AU (2) AU2152102A (sl)
BR (1) BR0116010A (sl)
CA (1) CA2431199C (sl)
CU (1) CU22979A1 (sl)
CY (1) CY1108474T1 (sl)
DE (1) DE60135248D1 (sl)
DK (1) DK1350521T3 (sl)
EA (1) EA007381B1 (sl)
ES (1) ES2311036T3 (sl)
HK (1) HK1073244A1 (sl)
MX (1) MXPA03005030A (sl)
MY (1) MY138833A (sl)
NZ (1) NZ526284A (sl)
PE (1) PE20020695A1 (sl)
PT (1) PT1350521E (sl)
SI (1) SI1350521T1 (sl)
UY (1) UY27058A1 (sl)
WO (1) WO2002045747A1 (sl)
ZA (1) ZA200304415B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
RU2537245C2 (ru) * 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
MX2010007841A (es) 2008-01-17 2010-09-28 Irm Llc Anticuerpos anti-trkb mejorados.
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CA3053239A1 (en) 2017-02-17 2018-08-23 George Todaro Use of tgf alpha for the treatment of diseases and disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH01221326A (ja) * 1988-02-29 1989-09-04 Toyo Jozo Co Ltd 悪性腫瘍細胞障害剤
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
DE69327620T2 (de) * 1992-08-18 2000-08-03 Centro De Immunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
NZ511550A (en) * 1997-05-12 2005-03-24 Aphton Corp CCK-B/gastrin receptor inhibitors for the treatment of tumors
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
JP2002514573A (ja) * 1998-05-08 2002-05-21 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 能動的なワクチン接種のための組成物および方法
WO1999060023A1 (en) * 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
EP1303533A2 (en) * 2000-05-05 2003-04-23 Aphton Corporation Chimeric peptide immunogens, their preparation and use
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Also Published As

Publication number Publication date
AU2002221521B2 (en) 2007-01-04
AR031641A1 (es) 2003-09-24
US20020160014A1 (en) 2002-10-31
JP2010150286A (ja) 2010-07-08
EA200300646A1 (ru) 2003-10-30
CY1108474T1 (el) 2014-04-09
CN1326566C (zh) 2007-07-18
ES2311036T3 (es) 2009-02-01
EP1350521A1 (en) 2003-10-08
PE20020695A1 (es) 2002-09-23
UY27058A1 (es) 2002-03-22
DE60135248D1 (de) 2008-09-18
CA2431199C (en) 2011-10-04
MY138833A (en) 2009-07-31
PT1350521E (pt) 2008-11-14
ZA200304415B (en) 2004-07-07
KR20030064416A (ko) 2003-07-31
JP2005519023A (ja) 2005-06-30
BR0116010A (pt) 2004-01-06
EP2005996A2 (en) 2008-12-24
WO2002045747A1 (es) 2002-06-13
EP2005996A3 (en) 2012-01-25
HK1073244A1 (en) 2005-09-30
ATE403438T1 (de) 2008-08-15
US20060188497A1 (en) 2006-08-24
SI1350521T1 (sl) 2008-12-31
CA2431199A1 (en) 2002-06-13
EP1350521B1 (en) 2008-08-06
EA007381B1 (ru) 2006-10-27
US7744871B2 (en) 2010-06-29
NZ526284A (en) 2004-11-26
CU22979A1 (es) 2004-09-09
CN1592636A (zh) 2005-03-09
AU2152102A (en) 2002-06-18
MXPA03005030A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DK2412368T3 (da) Sammensætning til behandling af ar
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
NO20034436L (no) Immunoterapeutiske kombinasjoner for behandling av tumorer som over-uttrykker gangliosider
HK1073244A1 (en) Immunotherapeutic kit for the treatment of tumors
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
AU2002221521A1 (en) Immunotherapeutic combinations for the treatment of tumors
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1311267T3 (da) Retroviral immunoterapi
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DE60211737D1 (de) Hochfrequenz-heizvorrichtung
DK1567524T3 (da) Thia-epothilonderivater til behandling af cancer
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne